Constitution Capital LLC Has $2 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Constitution Capital LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 12.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,342 shares of the company’s stock after selling 1,685 shares during the quarter. Johnson & Johnson makes up about 1.1% of Constitution Capital LLC’s investment portfolio, making the stock its 20th largest position. Constitution Capital LLC’s holdings in Johnson & Johnson were worth $2,000,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Summit Wealth Partners LLC boosted its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock worth $1,463,000 after purchasing an additional 61 shares during the period. Citizens & Northern Corp grew its stake in Johnson & Johnson by 3.5% during the second quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock valued at $275,000 after acquiring an additional 63 shares in the last quarter. Eagle Wealth Strategies LLC increased its holdings in Johnson & Johnson by 2.8% in the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after acquiring an additional 63 shares during the last quarter. Epic Trust Investment Advisors LLC lifted its stake in Johnson & Johnson by 3.6% in the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock worth $268,000 after purchasing an additional 64 shares in the last quarter. Finally, Pine Harbor Wealth Management LLC grew its position in shares of Johnson & Johnson by 1.9% during the second quarter. Pine Harbor Wealth Management LLC now owns 3,472 shares of the company’s stock valued at $507,000 after purchasing an additional 64 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 0.1 %

JNJ traded down $0.24 during trading hours on Monday, reaching $161.22. 412,052 shares of the company’s stock traded hands, compared to its average volume of 7,006,058. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $162.59 and a 200 day moving average price of $154.46. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The firm has a market capitalization of $388.00 billion, a PE ratio of 10.07, a PEG ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same period in the prior year, the business posted $2.80 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.08%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on JNJ shares. Royal Bank of Canada increased their price target on Johnson & Johnson from $175.00 to $178.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Thursday. The Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Finally, Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $174.31.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.